These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 29528278)

  • 21. [Methicillin-resistant Staphylococcus aureus infection and its treatment in burned patients].
    Huan JN; Chen YL; Ge SD
    Zhonghua Wai Ke Za Zhi; 1994 Apr; 32(4):244-5. PubMed ID: 7842932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chitosan and phospholipid assisted topical fusidic acid drug delivery in burn wound: Strategies to conquer pharmaceutical and clinical challenges, opportunities and future panorama.
    Jyoti K; Malik G; Chaudhary M; Sharma M; Goswami M; Katare OP; Singh SB; Madan J
    Int J Biol Macromol; 2020 Oct; 161():325-335. PubMed ID: 32485249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Genotyping and drug resistance of methicillin-resistant Staphylococcus aureus].
    Yao M; Guan L; Jia W; Wang L; Li G; Wu X; Sun T
    Zhonghua Shao Shang Za Zhi; 2014 Oct; 30(5):428-32. PubMed ID: 25572893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Membrane-Active Amphipathic Peptide WRL3 with in Vitro Antibiofilm Capability and in Vivo Efficacy in Treating Methicillin-Resistant Staphylococcus aureus Burn Wound Infections.
    Ma Z; Han J; Chang B; Gao L; Lu Z; Lu F; Zhao H; Zhang C; Bie X
    ACS Infect Dis; 2017 Nov; 3(11):820-832. PubMed ID: 28885829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An aryl isonitrile compound with an improved physicochemical profile that is effective in two mouse models of multidrug-resistant Staphylococcus aureus infection.
    Mohammad H; Kyei-Baffour K; Abutaleb NS; Dai M; Seleem MN
    J Glob Antimicrob Resist; 2019 Dec; 19():1-7. PubMed ID: 31051286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chitosan-tailored lipidic nanoconstructs of Fusidic acid as promising vehicle for wound infections: An explorative study.
    Thakur K; Sharma G; Singh B; Chhibber S; Patil AB; Katare OP
    Int J Biol Macromol; 2018 Aug; 115():1012-1025. PubMed ID: 29680503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biofilm formation and antimicrobial resistance in methicillin-resistant Staphylococcus aureus isolated from burn patients, Iran.
    Ohadian Moghadam S; Pourmand MR; Aminharati F
    J Infect Dev Ctries; 2014 Dec; 8(12):1511-7. PubMed ID: 25500648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topical Bactroban (mupirocin): efficacy in treating burn wounds infected with methicillin-resistant staphylococci.
    Strock LL; Lee MM; Rutan RL; Desai MH; Robson MC; Herndon DN; Heggers JP
    J Burn Care Rehabil; 1990; 11(5):454-9. PubMed ID: 2123203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Azithromycin-loaded liposomes for enhanced topical treatment of methicillin-resistant Staphyloccocus aureus (MRSA) infections.
    Rukavina Z; Šegvić Klarić M; Filipović-Grčić J; Lovrić J; Vanić Ž
    Int J Pharm; 2018 Dec; 553(1-2):109-119. PubMed ID: 30312749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Formulation and Molecular Dynamics Simulations of a Fusidic Acid Nanosuspension for Simultaneously Enhancing Solubility and Antibacterial Activity.
    Omolo CA; Kalhapure RS; Agrawal N; Rambharose S; Mocktar C; Govender T
    Mol Pharm; 2018 Aug; 15(8):3512-3526. PubMed ID: 29953816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fusidic acid resistance in community isolates of methicillin susceptible Staphylococcus aureus and the use of topical fusidic acid: a retrospective case-control study.
    Mason BW; Howard AJ
    Int J Antimicrob Agents; 2004 Mar; 23(3):300-3. PubMed ID: 15164973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterisation of SCCmec elements in methicillin-resistant Staphylococcus aureus isolated from burn patients.
    Namvar AE; Afshar M; Asghari B; Rastegar Lari A
    Burns; 2014 Jun; 40(4):708-12. PubMed ID: 24211088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increasing resistance to fusidic acid among clinical isolates of MRSA.
    Wang JT; Huang IW; Chang SC; Tan MC; Lai JF; Chen PY; Lauderdale TL
    J Antimicrob Chemother; 2017 Feb; 72(2):616-618. PubMed ID: 27733516
    [No Abstract]   [Full Text] [Related]  

  • 34. [Analysis of the pathogenic characteristics of 162 severely burned patients with bloodstream infection].
    Gong YL; Yang ZC; Yin SP; Liu MX; Zhang C; Luo XQ; Peng YZ
    Zhonghua Shao Shang Za Zhi; 2016 Sep; 32(9):529-35. PubMed ID: 27647068
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro antimicrobial findings for fusidic acid tested against contemporary (2008-2009) gram-positive organisms collected in the United States.
    Jones RN; Mendes RE; Sader HS; Castanheira M
    Clin Infect Dis; 2011 Jun; 52 Suppl 7():S477-86. PubMed ID: 21546624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eradication of methicillin-resistant Staphylococcus aureus infection by nanoliposomes loaded with gentamicin and oleic acid.
    Atashbeyk DG; Khameneh B; Tafaghodi M; Fazly Bazzaz BS
    Pharm Biol; 2014 Nov; 52(11):1423-8. PubMed ID: 25026343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determining the effect of an oak bark formulation on methicillin-resistant staphylococcus aureus and wound healing in porcine wound models.
    Davis SC; Mertz PM
    Ostomy Wound Manage; 2008 Oct; 54(10):16-8, 20, 22-5. PubMed ID: 18927480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High usage of topical fusidic acid and rapid clonal expansion of fusidic acid-resistant Staphylococcus aureus: a cautionary tale.
    Williamson DA; Monecke S; Heffernan H; Ritchie SR; Roberts SA; Upton A; Thomas MG; Fraser JD
    Clin Infect Dis; 2014 Nov; 59(10):1451-4. PubMed ID: 25139961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efforts to support the development of fusidic acid in the United States.
    Fernandes P; Pereira D
    Clin Infect Dis; 2011 Jun; 52 Suppl 7():S542-6. PubMed ID: 21546632
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fusidic acid for the treatment of bone and joint infections caused by meticillin-resistant Staphylococcus aureus.
    Wang JL; Tang HJ; Hsieh PH; Chiu FY; Chen YH; Chang MC; Huang CT; Liu CP; Lau YJ; Hwang KP; Ko WC; Wang CT; Liu CY; Liu CL; Hsueh PR
    Int J Antimicrob Agents; 2012 Aug; 40(2):103-7. PubMed ID: 22612900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.